120 related articles for article (PubMed ID: 21978467)
21. Drug resistance in multiple myeloma.
Robak P; Drozdz I; Szemraj J; Robak T
Cancer Treat Rev; 2018 Nov; 70():199-208. PubMed ID: 30245231
[TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.
Soriano GP; Besse L; Li N; Kraus M; Besse A; Meeuwenoord N; Bader J; Everts B; den Dulk H; Overkleeft HS; Florea BI; Driessen C
Leukemia; 2016 Nov; 30(11):2198-2207. PubMed ID: 27118406
[TBL] [Abstract][Full Text] [Related]
23. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells.
Pelon M; Krzeminski P; Tracz-Gaszewska Z; Misiewicz-Krzeminska I
Front Pharmacol; 2024; 15():1351565. PubMed ID: 38500772
[TBL] [Abstract][Full Text] [Related]
24. Single-cell morphological and transcriptome analysis unveil inhibitors of polyploid giant breast cancer cells in vitro.
Zhou M; Ma Y; Chiang CC; Rock EC; Butler SC; Anne R; Yatsenko S; Gong Y; Chen YC
Commun Biol; 2023 Dec; 6(1):1301. PubMed ID: 38129519
[TBL] [Abstract][Full Text] [Related]
25. Dual RNase activity of IRE1 as a target for anticancer therapies.
Bartoszewska S; Sławski J; Collawn JF; Bartoszewski R
J Cell Commun Signal; 2023 Dec; 17(4):1145-1161. PubMed ID: 37721642
[TBL] [Abstract][Full Text] [Related]
26. Targeting TGF-β signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction.
Rana PS; Soler DC; Kort J; Driscoll JJ
Front Cell Dev Biol; 2022; 10():1059715. PubMed ID: 36578789
[TBL] [Abstract][Full Text] [Related]
27. Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance.
Mejia Saldarriaga M; Darwiche W; Jayabalan D; Monge J; Rosenbaum C; Pearse RN; Niesvizky R; Bustoros M
Front Oncol; 2022; 12():1020011. PubMed ID: 36387095
[TBL] [Abstract][Full Text] [Related]
28. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
Yang Y; Gao Y; Huang J; Yang Z; Luo H; Wang F; Xu J; Cui Y; Ding H; Lin Z; Zhai X; Qu Y; Zhang L; Liu T; Ye L; Niu T; Zheng Y
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040812
[TBL] [Abstract][Full Text] [Related]
29. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
Schwestermann J; Besse A; Driessen C; Besse L
Front Oncol; 2022; 12():899272. PubMed ID: 35692781
[TBL] [Abstract][Full Text] [Related]
30. The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma.
Sellin M; Berg S; Hagen P; Zhang J
Transl Oncol; 2022 Aug; 22():101448. PubMed ID: 35660848
[TBL] [Abstract][Full Text] [Related]
31. Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance.
Leonardo-Sousa C; Carvalho AN; Guedes RA; Fernandes PMP; Aniceto N; Salvador JAR; Gama MJ; Guedes RC
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408601
[TBL] [Abstract][Full Text] [Related]
32. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.
Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L
J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
Robak P; Szemraj J; Mikulski D; Drozdz I; Juszczak K; Jarych D; Misiewicz M; Kościelny K; Fendler W; Robak T
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768548
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological targeting of endoplasmic reticulum stress in disease.
Marciniak SJ; Chambers JE; Ron D
Nat Rev Drug Discov; 2022 Feb; 21(2):115-140. PubMed ID: 34702991
[TBL] [Abstract][Full Text] [Related]
35. PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse.
Thura M; Ye Z; Al-Aidaroos AQ; Xiong Q; Ong JY; Gupta A; Li J; Guo K; Ang KH; Zeng Q
Commun Biol; 2021 Jul; 4(1):923. PubMed ID: 34326464
[TBL] [Abstract][Full Text] [Related]
36. Context-dependent effects of whole-genome duplication during mammary tumor recurrence.
Newcomb R; Dean E; McKinney BJ; Alvarez JV
Sci Rep; 2021 Jul; 11(1):14932. PubMed ID: 34294755
[TBL] [Abstract][Full Text] [Related]
37. Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death.
Caillot M; Dakik H; Mazurier F; Sola B
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34067602
[TBL] [Abstract][Full Text] [Related]
38. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
[TBL] [Abstract][Full Text] [Related]
39. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.
Robak P; Jarych D; Mikulski D; Dróżdż I; Węgłowska E; Kotkowska A; Misiewicz M; Smolewski P; Stawiski K; Fendler W; Szemraj J; Robak T
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668794
[TBL] [Abstract][Full Text] [Related]
40. Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells.
Tsubaki M; Takeda T; Matsuda T; Seki S; Tomonari Y; Koizumi S; Nagatakiya M; Katsuyama M; Yamamoto Y; Tsurushima K; Ishizaka T; Nishida S
Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33406639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
